BioMarin Pharmaceuticals BMRN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | $426.86M+155% | $167.65M+18.2% | $141.81M+321% | ||
| $79.56M-17.5% | $96.43M-7.6% | $104.39M+2.4% | $101.97M-5.6% | ||
| $181.41M-10.0% | $201.57M-2.7% | $207.1M+5.5% | $196.31M-0.5% | ||
| —— | $56.1M+221% | -$46.23M+11.2% | -$52.09M-234% | ||
| $2.62M-21.9% | $3.36M-19.8% | $4.19M+1.7% | $4.12M-0.7% | ||
| —— | $19.89M— | —— | $0— | ||
| —— | —— | $204.33M— | —— | ||
| $116.93M— | —— | $157.06M+130% | $68.26M+94.7% | ||
| —— | —— | $68.85M— | —— | ||
| $38.57M-47.7% | $73.7M+137% | $31.15M+56.9% | $19.86M+201% | ||
| —— | $14.76M-37.4% | $23.59M+240% | $6.93M— | ||
| $4.63M+123% | -$20.14M-5,616% | $365K-82.1% | $2.04M— | ||
| -$8.89M— | —— | —— | -$7.82M— | ||
| $827.99M+44.5% | $572.84M+260% | $159.26M-9.5% | $175.9M-42.2% | ||
| $103.04M+20.6% | $85.42M-11.7% | $96.69M-20.1% | $120.96M+26.6% | ||
| $355.88M-13.3% | $410.25M-52.8% | $868.5M+42.0% | $611.81M-34.7% | ||
| $337.8M-46.6% | $633.02M-26.8% | $864.86M+39.5% | $620M-10.3% | ||
| —— | -$1.14M— | —— | —— | ||
| -$414.24M— | —— | —— | —— | ||
| —— | —— | —— | $0— | ||
| $55.97M-27.8% | $77.56M+1.6% | $76.32M+40.6% | $54.28M+18.5% | ||
| —— | —— | —— | —— | ||
| -$45.55M— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $368.84M+96.5% | $187.72M— | —— | —— | ||
| $96.21M+68.0% | $57.27M-21.9% | $73.31M+34.8% | $54.37M+200% | ||
| $4.8M-42.5% | $8.35M-9.6% | $9.23M— | —— | ||
| $2.62M-21.9% | $3.36M-19.8% | $4.19M+1.7% | $4.12M-0.7% | ||
| —— | $19.89M— | —— | $0— | ||
| -$4.46M— | —— | -$30.45M— | —— | ||
| -$8.89M— | —— | —— | -$7.82M— | ||
| $4.63M+123% | -$20.14M-5,616% | $365K-82.1% | $2.04M— | ||
| —— | -$1.14M— | —— | —— | ||
| $337.8M-46.6% | $633.02M-26.8% | $864.86M+39.5% | $620M-10.3% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $6.33M-20.9% | $8M— | —— | ||
| $724.96M+48.7% | $487.42M— | —— | —— | ||
| $724.96M+48.7% | $487.42M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
